/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Kiniksa Pharmaceuticals International (KNSA) generated about $754 million in revenue and $73 million in net income (a 9.7% net margin) over the trailing twelve months, growing at roughly 104.8% a year. Figures are from SEC filings; this is analysis, not investment advice.
Kiniksa Pharmaceuticals International generated about $754 million in revenue over the trailing twelve months. Revenue has grown at roughly 104.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Yes, Kiniksa Pharmaceuticals International reported about $73 million in net income over the trailing twelve months, a net profit margin of roughly 9.7%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Kiniksa Pharmaceuticals International runs a gross margin of about 89.3%, an operating margin of about 12.4%, a net margin of about 9.7%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Kiniksa Pharmaceuticals International's revenue has compounded at roughly 104.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside KNSA's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 28 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 29 Jul 2026. How this is calculated.
Fiscal year ends Dec.